Ebola critical care considerations. Diagnostic tests may take up to 8 h to receive a result.
|
|
- Victor Perkins
- 5 years ago
- Views:
Transcription
1 Clinical overview articles Update in Anaesthesia Ebola critical care considerations Lisa Molus and Paul Bush Correspondence: Originally published as Anaesthesia Tutorial of the Week 315, 16 April Edited by Niraj Niranjan and Harry Singh Summary Although the threat of imported cases to the UK and other international countries is low, there remains the distinct possibility that further cases may occur. Consider Ebola virus disease (EVD) as a differential diagnosis in anyone with a positive exposure history and recent fever 37.5 C. If deemed at risk, immediate isolation in a ward-level bed and discussion with local infectious disease service is paramount. Diagnostic tests may take up to 8 h to receive a result. EVD has a high mortality but survival outcomes improve with aggressive supportive care with intravenous fluid and electrolyte replacement. Local escalation policies should be pre-agreed and followed. All confirmed EVD cases should be transferred to a specialist High Level Isolation Facility for further management. Lisa Molus CT2 Anaesthetics Sunderland Royal Infirmary UK Paul Bush Consultant in Anaesthetics and Intensive Care University Hospital North Durham UK INTRODUCTION Ebola virus disease (EVD), previously known as Ebola haemorrhagic fever, is a rare, life-threatening viral illness caused by infection with one of the Ebola virus strains. The most recent epidemic of EVD, beginning in March 2014, has been the largest recorded outbreak, in terms of both geographical spread and case numbers. It has affected multiple countries in West Africa, amongst which the most affected are Guinea, Liberia and Sierra Leone. In late July the World Health Organization (WHO) declared the outbreak a Grade 3 emergency response and, later, in early August, a Public health emergency of international concern. Cases have been reported in Nigeria, Senegal, Mali, the USA, Spain and the UK. The management of EVD raises a number of practical, logistic and ethical issues. This article aims to discuss the management of suspected and confirmed cases of EVD from a critical care perspective. It is based on recent publications from WHO, the Centers for Disease Control and Prevention (CDC), Public Health England (PHE) and the North of England Critical Care Network (NoECCN). HISTORY EVD is caused by the genus Ebolavirus, which is part of the Filovirus family. Filoviruses can cause severe haemorrhagic fever in human and non-human primates. Four of the five known species of Ebolavirus can cause disease in humans: Zaire, Sudan, Tai Forest and Bundibugyo. The fifth species, Reston, has caused severe illness only in non-human primates. 1 Ebola was first discovered in 1976 in almost simultaneous outbreaks occurring in the Democratic Republic of Congo near the Ebola River, from which the disease takes its name, and in South Sudan. The disease then disappeared after 1979 and did not reappear again until 1994 in Gabon. Since 1994 sporadic outbreaks have been occurring with increasing frequency. 2 CURRENT EPIDEMIOLOGY The current (2014) epidemic is caused by the Zaire species. It is by far the most widespread and intense outbreak recorded and, as of 6 February 2015, a total of 22,495 clinically compatible cases of EVD, 48 Volume 31 final.indd 48 16/05/ :16
2 Figure 1. Cumulative clinically compatible cases in Guinea, Liberia and Sierra Leone as of 4 February including 8981 deaths, have been reported globally (Figure 1). This number is believed to be an under-representation, as many cases will be cared for outside the hospital setting. At present, there have been six non-medically repatriated cases of EVD diagnosed outside Africa: three imported cases (one in the UK and two in the USA) and three incidents of local transmission to health care workers (one in Spain and a further two in the USA). With regard to medically repatriated cases, a total of 18 patients with confirmed have been evacuated from Africa. Of these, 14 have been discharged from hospital and four have died. The Zaire species of Ebolavirus is one of the most virulent human pathogens known. The overall case fatality rates in the three intense transmission countries (Guinea, Liberia and Sierra Leone) are estimated to be as high as 71% whilst, among those hospitalised, mortality rates are slightly lower, at 60%. The mortality rate is seen to fall further in EVD cases being treated outside of Africa, at approximately 20%. The risk of further EVD cases being imported to Europe and the USA is still considered to be very low because robust monitoring and surveillance measures are in place. However, there remains a distinct possibility that additional cases may occur in the upcoming months, giving rise to concerns for the impact this may have on national health services. 3 PATHOGENESIS The natural reservoir of Ebola virus has not yet been identified. The first human case in an outbreak occurs through contact with the body fluids of an infected animal. Person-to-person transmission then follows through: direct contact with blood or body fluids (including but not limited to urine, saliva, faeces, vomit, breast milk, semen and sweat) of an infected individual contact with objects contaminated with infected fluids in the absence of strict infection control measures. Traditional burial practices in West Africa, where mourners have direct contact with the bodies of the deceased, have significantly driven the transmission of EVD. Transmission via sexual contact with a convalescent case is also possible as the virus is present in semen and vaginal fluids for up to 3 months after recovery. 2 Infection begins once the virus gains entry through unprotected mucous membranes, breaks in skin integrity or via the parenteral route. There is no evidence of transmission of EVD through intact skin or through small droplet spread, such as coughing or sneezing. The virus migrates to regional lymph nodes and subsequently disseminates to the liver, spleen and adrenal glands, affecting a number of target cells, including monocytes, macrophages, dendritic cells, endothelial cells, fibroblasts, hepatocytes, adrenal cortical cells and epithelial cells. Although not infected by Ebola virus, lymphocytes undergo apoptosis, resulting in decreased lymphocyte counts and an altered immune response by modulation of gene expression. An early antibody response and high lymphocytic count during the infection are associated with survival. Hepatocellular and adrenocortical necrosis occur, causing coagulopathy and shock from impaired steroid synthesis respectively Volume 31 final.indd 49 16/05/ :16
3 Ebola virus appears to induce cytokine and other proinflammatory mediator release with subsequent loss of vascular integrity and coagulation defects ultimately resulting in multiorgan failure and shock. 4 The pathogenesis of shock is multifactorial and includes fluid loss, fluid sequestration, coagulopathy and sepsis due to secondary infections. CLINICAL PRESENTATION Patients with EVD will develop symptoms within 21 days of infection and any symptoms following this period will not be due to Ebola virus. The onset of symptoms typically occurs after an incubation period of approximately 9 11 days. Table 1 outlines the symptoms of EVD. Such non-specific symptoms can be easily mistaken for those of other infectious diseases such as malaria or typhoid fever, or with any other viral or bacterial infection, so a comprehensive travel and exposure history must be obtained. Patients with fatal disease typically develop more severe clinical signs early during infection and usually succumb to the disease between days 6 and 16. In less severe cases, patients have fever for several days and improve around day 6. Risk factors associated with a poor outcome in the affected West African countries are shown in Table 2. 5 INFECTION CONTROL Prior to isolation, if the patient has been in a public area, the hospital lead for infection control and the local health protection team must be notified, and the area cornered off and decontaminated. All staff Table 1. Early and late signs and symptoms of Ebola virus disease 5 Early Fever Rash (maculopapular) Sore throat Myalgia and arthralgia Malaise Severe headache Late Severe watery diarrhoea Vomiting Abdominal pain Petechiae Hypovolaemic shock Haemorrhagic manifestations, e.g. mucosal or gastrointestinal Table 2. Risk factors associated with a poor outcome in West African countries 5 Age > 45 years Unexplained haemorrhage Associated symptoms such as: chest pain shortness of breath headache confusion and convulsions and members of the public who may have come into physical contact with the patient or body fluids should be assessed. Infection control measures are a critical part of clinical management. Person-to-person transmission of Ebola virus requires direct contact with body fluids (e.g. blood, faeces or vomit) from a person who has developed symptoms. Therefore, in a secondary care setting, the rapid identification and subsequent isolation of high-risk patients is paramount. The patient should be isolated in a single room with an adjacent contained space to be used for the removal of personal protective equipment (PPE) and waste disposal. Only staff trained in the correct use of PPE should have patient contact. Staff should attend the patient in pairs with a third member in the relevant PPE outside the room to assist as required. A fourth member of staff should act as a safety officer, ensuring correct PPE use and adherence to local protocols for the safe donning and doffing of PPE. 6 The use of PPE is mandatory, and guidance from the CDC sets out protection standards for dealing with suspected cases of EVD. Recommended PPE includes the following: hand hygiene with soap and water or an alcohol based hand rub single-use double gloves with extra-long cuffs fluid-resistant single-use coveralls extending to the mid-calf fluid-resistant single-use aprons if patients have vomiting or diarrhoea respiratory protective equipment (RPE) to reduce the risk of aerosol spread such as: powered air-purifying respirator (PAPR) with a full face shield, helmet or headpiece N95 or higher respirator in combination with disposable surgical hood extending to shoulders and single-use full face shield. 7 Note that the above are recommendations and that individual facilities may elect to use PPE that varies from that outlined depending on local resources. The key to effective and safe use of any PPE is through consistent implementation by repeated training and practice. Facilities should standardise the PPE in use and provide clear written protocols to avoid the risk of contamination. 7 CLEANING AND WASTE MANAGEMENT Contaminated equipment or surfaces should be cleaned and disinfected in a timely manner using standard hospital disinfectants (e.g. 0.5% chlorine solution). Contaminated material must be immediately segregated at the point of generation, sealed in appropriately labelled containers and destroyed within 24 hours. The preferred method of waste disposal is autoclaving with the contents appropriately disposed of in a designated pit Volume 31 final.indd 50 16/05/ :16
4 Handling of human remains should be kept to a minimum. Appropriately trained personnel must use full PPE when handling the remains of a suspected or confirmed case of EVD. The body should be placed in a leak-proof double bag, with the surface of each body bag being decontaminated with a suitable disinfectant. The body should immediately be transported to the mortuary or the cemetery and buried promptly. Spraying, washing or embalming of remains in preparation for burial should be discouraged. Owing to the highly infectious nature of the remains, post-mortem examinations should be limited to essential evaluations only and, again, must be carried out by trained personnel wearing full PPE. 8 DIAGNOSIS The diagnosis of EVD should follow a step-wise approach comprising a comprehensive history, physical examination and relevant investigations. A high index of suspicion of EVD should be present when faced with any individual manifesting the signs and symptoms detailed above along with a positive exposure history. Current practice in the UK is based upon recent guidelines published by the College of Emergency Medicine. patients are suspected to be at high risk of EVD if: 1. they have travelled from one of the affected areas (currently Guinea, Liberia and Sierra Leone) or have had contact with an individual with EVD within the previous 21 days, and 2. they have a fever ( 37.5 C) or history of fever in the past 24 hours. 6 However, as the symptoms of EVD are non-specific and may mimic those of other diseases, a definitive diagnosis can be made only by using specific laboratory diagnostic tests including enzyme-linked immunosorbent assay (ELISA) testing, polymerase chain reaction (PCR) and virus isolation. Ebola virus can be detected in serum samples only after the onset of symptoms, when the viral load is increasing. Diagnostic tests are usually performed on samples of serum and EDTA-treated blood and/or urine. In the UK, samples are sent to the Rare and Imported Pathogens Laboratory (RIPL) in Wiltshire, England. In addition to EVD, all samples are tested for other potential causes of fever that the patient may have been exposed to, including, but not limited, to Marburg virus disease, Dengue fever and malaria. For urgent samples, results may be available within 7 8 hours of sample receipt. Positive results are immediately telephoned to the referring clinician to aid in the timely patient management, infection control and public health response. 9 It may take up to 3 days after the onset of symptoms for the virus to reach detectable levels. It is therefore essential, following an initial negative sample, to send a second sample for testing after at least 48 hours owing to the possibility of a false-negative result. 10 Other supplementary laboratory investigations include haematological and biochemical tests. Findings may demonstrate low white blood cell counts followed later by elevated neutrophils. Serum amylase and hepatic transaminases may be raised, reflecting pancreatic and hepatic involvement. Blood coagulation tests may demonstrate a picture consistent with DIC such as prolonged prothrombin time (PT) and partial thromboplastin times (PTT), elevated fibrin degradation products and thrombocytopenia. 5 MANAGEMENT The increasing international response to the current outbreak has meant that a large number of international health care and military staff have been deployed to aid countries where transmission is widespread. Such workers have been identified as being at obvious risk of EVD, and the CDC and other national agencies have issued guidance for the monitoring, surveillance and, if indicated, escalation plans for returning staff based on their exposure risk. 11 Individuals with suspected EVD are likely to initially present to a peripheral hospital so acute health services should have local management protocols in place. Discussion with infectious disease clinicians will help determine whether transfer to a high-level infection unit (HLIU) is indicated. In peripheral hospitals, it is recommended that cases be managed with the best available PPE, in a ward-level isolation room rather than a critical care setting. The decision to escalate or de-escalate care should be made on a case-by-case basis, taking into consideration the potential risks to the patient and staff. This decision-making process raises many ethical and practical issues so must be based on agreement between at least two local consultants (such as emergency department and critical care consultants) and advice from an infectious disease consultant. In confirmed cases, a number of key teams are alerted including the outbreak control team, public health and senior government officials, and the clinical team at the nearest HLIU. 12 Currently there is no licensed treatment or vaccine for EVD and the mainstay of treatment is primarily supportive. Care focuses on the early detection and supportive care of complications such as hypoxia, hypovolaemia, electrolyte and coagulation abnormalities, septic shock, multiorgan failure and disseminated intravascular coagulation (DIC). This standard supportive care should be provided by the hospital concerned within the limitations of the strict infection control measures. Monitoring The monitoring of patients vital signs, fluid balance and neurological status through non-invasive means (e.g. pulse oximetry, heart monitor, non-invasive blood pressure) should be carried out on a frequent basis guided by the patient s clinical condition. Accurate documentation of fluid balance may be difficult particularly in the setting of vomiting and diarrhoea; therefore, hourly monitoring of urine output via a Foley catheter and urometer is essential Volume 31 final.indd 51 16/05/ :16
5 If available, invasive arterial blood pressure monitoring should be considered in those with haemodynamic instability requiring vasopressor support or when frequent blood samples are being taken. Insertion of a central venous line (CVL) solely for central venous pressure (CVP) monitoring is not recommended and in general the use of any form of invasive monitoring should be limited to reduce the risk of exposure to health care staff. Airway management and ventilation Respiratory involvement is not a common feature of EVD, although in severe cases respiratory failure may occur. Airway management may otherwise be required to protect the airway from aspiration in those with reduced level of consciousness or upper gastrointestinal haemorrhage. The CDC strongly recommend that aerosol-generating procedures such non-invasive ventilation, bronchoscopy, sputum induction, intubation and extubation and open suctioning of airways be avoided if at all possible. In addition, ventilatory support has yet to demonstrate a significant improvement in survival rates and therefore may not be offered depending on local protocol. If ventilatory support is to be offered, the Canadian Critical Care Society recommends early intubation with traditional mechanical ventilation in a negative pressure isolation room by highly experienced clinicians wearing appropriate PPE. 13 Cardiovascular support and intravenous access Careful attention to intravascular volume status and aggressive administration of fluids and electrolytes (with a special focus on potassium, calcium and bicarbonate supplementation) constitutes the first step in a series of supportive care interventions. In the non-critically ill patient this should be achieved via the oral route. Intravenous access is required in those unable to tolerate the oral route or in the presence of haemodynamic instability. Hartmann s or Ringer s lactate has been suggested as the fluid of choice for volume replacement. Large-bore peripheral intravenous (IV) access is suitable for those with milder disease with central venous access required for those needing IV electrolyte replacement or with poor peripheral access. In the event of the need to establish central venous access, the risk of injury and exposure can be minimised by having an experienced clinician conduct the procedure under ultrasound guidance. Needle-less systems may be used to avoid sharps injuries and the use of non-suture securing devices is advocated. Cardiovascular support with vasopressors may be indicated, these may be administered via either the peripheral or central route depending on local protocol. Vigilance must be taken with fluid replacement as with the systemic inflammatory response and loss of vascular integrity, profound third space losses have been observed. The correction of haematological and coagulation abnormalities with blood products may also be necessary. 13 Renal support Renal failure is common in severe cases. Dialysis for renal failure is considered a high-risk intervention for health care staff and the Royal Free Hospital in London has therefore ruled out offering this. In the USA, however, the CDC recommend that the care of patients with EVD should be undertaken in a hospital with the capacity to perform continuous renal replacement therapy (CRRT). This highlights the importance of regional and national guidelines in outlining clear escalation and management policies. 14 Symptom management Symptoms control is a significant component of EVD management (Table 3). Antibiotics and experimental therapies The treatment of secondary bacterial infections and use of broadspectrum antibiotics has been suggested in patients with evidence of septic shock and secondary infection. The early discontinuation of antibiotic therapy should be considered if microbiology results and other investigations do not reveal bacterial superinfection. Other management options may include the early utilisation of Table 3. Symptoms of EVD and the appropriate management 12 Symptom Pain Fever Dyspnoea Seizure Nausea and vomiting Poor oral intake Agitation Management Opiates titrated to effect e.g. fentanyl, morphine Paracetamol (max. 4 g per 24 hours), lower dose in hepatic dysfunction Non-steroidal anti-inflammatory drugs should be avoided because of their platelet inhibition and renal effects Supplemental oxygen Airway management. Benzodiazepines. Laboratory investigations (Na +, glucose). CT of the head if focal signs are present Antiemetics. Consider nasogastric tube and suction Where available, delayed total parenteral nutrition if enteral not tolerated Haloperidol 52 Volume 31 final.indd 52 16/05/ :16
6 experimental monoclonal antibody therapy such as ZMapp (Mapp Biopharmaceuticals Inc, San Diego, CA, USA). The clinical benefit of ZMapp remains unproven and further trials are required to assess efficacy. Beyond Zmapp, the development and testing of other antiviral therapies and experimental vaccines is also picking up pace. 5,15 Patients who make a successful recovery from EVD develop antibodies that last for at least 10 years. It is not known if people who recover are immune for life or if they can become infected with a different strain of Ebolavirus. 5 PAEDIATRIC CONSIDERATIONS There are additional issues that must be considered when managing suspected or confirmed EVD in the paediatric population. There is limited information on the current outbreak and the impacts this has on children. However, because their circulating blood volumes are smaller, children are more likely to become fluid depleted as a result of vomiting or diarrhoea, so without rapid intervention, they have the potential to deteriorate more rapidly than adults. Thus, it may be desirable to transfer children to a specialist HLIF at an earlier stage (i.e. prior to laboratory diagnosis of EVD) than would be the case for an adult. Children depend on their parents or caregivers for their physical needs and psychological support so the isolation and quarantine of children poses a challenge. With most infectious diseases, children are often isolated with a parent. However, in the case of EVD, because of the risk of parental exposure, parents may need to be separated from their child. This may impact on the child s compliance with treatment especially when confronted with clinical staff in full PPE. The decision to allow parents to accompany a child or to administer sedation to aid with management must be made on a case-by-case basis. Hospital protocols, public health advice and the level of exposure between parent and child that may have occurred before seeking medical care must all be taken into consideration. 16 ETHICAL ISSUES OF ESCALATION The prioritisation and allocation of finite critical care resources occurs routinely throughout the health service. The provision of critical care is based on clinical decisions allowing for the most effective and ethically sound allocation of resources, free from external, political and public influences. In EVD the most likely situation is that small numbers of patients will require simultaneous treatment. However, the treatment of a single EVD patient will require extraordinary resources. If exceptional demand is placed on critical care, such that resources cannot be provided to all patients who have the ability to benefit, the threshold for accessing critical care consequently rises. Despite EVD s current prominence in the media and in public interest, the clinical and ethical principles underpinning such decision-making processes remain unchanged. This must be done on an individual case-by-case basis, with the patient with the higher clinical likelihood of benefit being given precedence. In the case of EVD, there are two main conflicting ethical stances regarding the allocation of scarce critical care resources. The first approach attempts to weigh the potential benefits against harm and, in doing so, a balanced judgement can be made which results in the greatest net benefit. Taking into consideration the high mortality rate, the high risk of secondary contamination to health care staff and the subsequent denial of effective treatments for other patients due to redistribution of resources, the refusal of level 3 care for patients with confirmed EVD can be justified as the overall perceived harm outweighs the limited expected gains. The opposing view considers our duties and obligations and how best they may be met. Here the argument is that, with strict adherence to infection control measures, the risk to staff and other patients is acceptably low, the reduction in mortality rates with relatively simple supportive care considerable, and the redistribution of work and resources possible with good organisation, planning and communication. This approach would support the provision of critical care interventions to patients with EVD. 12 PRACTICAL ISSUES OF ESCALATION Currently, there is limited evidence to support the provision of critical care in the management of EVD as, unlike optimum supportive care, the addition of renal and ventilatory support has yet to demonstrate a significant improvement in survival rates. This attitude may be set to change, however, as clinical experience is continually increasing as a result of the treatment of EVD patients in the USA and Europe. In practice, the escalation of EVD patients to a critical care setting in a peripheral hospital presents many challenges. In Texas, for example, a 25-bed critical care unit was closed for several weeks while an imported patient with EVD was treated. The closure of a critical care unit would have a significant impact on the ability of other patients to access a higher level of care. This may result in the restriction of surgeries, conversion of theatre recovery areas and of level 1 and 2 beds to level 3 and the rapid retraining and redeployment of medical and nursing staff. Devoting such resources to patients with EVD is likely to affect the hospital s ability to staff other services. It is therefore recommended that no peripheral hospital should be required to provide level 3 care to a patient with confirmed EVD. Such patients should ideally be managed in an isolated ward-level bed prior to transfer to a specialist HLIF Volume 31 final.indd 53 16/05/ :16
7 At present, in the UK there is only one HLIF at the Royal Free Hospital in London, comprising two specialist beds available for the management of patients with highly infectious diseases. Three additional infectious disease units in the cities of Newcastle, Sheffield and Liverpool provide surge capacity where EVD patients could be transferred in the event of a larger outbreak, making a total of 26 beds available in the UK. REFERENCES 1. Centers for Disease Control and Prevention (2013). Viral Hemorrhagic Fevers (VHFs): Filoviridae. Available: gov/vhf/virus-families/filoviridae.html (last accessed 14 December 2014). 2. Public Health England (2014). Ebola: overview, History, Origins and Transmission. Available at: publications/ebola-origins-reservoirs-transmission-and-guidelines (last accessed 14 December 2014). 3. Public Health England (2015). Ebola virus disease: epidemiological update: 6 February Available: government/uploads/system/uploads/attachment_data/ file/402217/evd_epidemiological_update_6_february.pdf (last accessed 13 February 2015). 4. Sullivan, N. Yang, Z. Nabel, G. Ebola virus pathogenesis: implications for vaccines and therapies. J Virology 2003; 77: Centers for Disease Control and Prevention (2015). Ebola Virus Disease Information for Clinicians in U.S. Healthcare Settings. Available: (last accessed 14 January 2015). 6. The College of Emergency Medicine, Public Health England. Ebola Guidance for Emergency Departments. CEM, London, Centers for Disease Control and Prevention (2014). Guidance on Personal Protective Equipment To Be Used by Healthcare Workers During Management of Patients with Ebola Virus Disease in U.S. Hospitals, Including Procedures for Putting On (Donning) and Removing (Doffing). Available: healthcareus/ppe/guidance.html. (accessed 10 February 2015). 8. World Health Organisation (2014). Interim Infection Prevention and Control Guidance for Care of Patients with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health- Care Settings, with Focus on Ebola. Available at: bitstream/10665/130596/1/who_his_sds_2014.4_eng. pdf?ua=1&ua=1&ua=1 (accessed 26 February 2015). 9. Public Health England (2014). PHE Microbiology Services VHF Sample Testing Queries. Available at: uploads/system/uploads/attachment_data/file/388011/phe_ Microbiology_Services_VHF_Sample_Testing_Queries.pdf (last accessed 12 January 2015). 10. World Health Organization (2014). Laboratory diagnosis of Ebola virus disease. Available at: bitstream/10665/134009/1/who_evd_guidance_lab_14.1_eng. pdf (last accessed 26 February 2015). 11. Centers for Disease Control and Prevention (2014). Interim U.S. Guidance for Monitoring and Movement of Persons with Potential Ebola Virus Exposure. Available at : exposure/monitoring-andmovement-of- persons-with-exposure. html (accessed 11 February 2015). 12. North of England Critical Care Network, NHS England. Guidelines for Escalation of Ebola Virus Disease. NoECCN, Canadian Critical Care Society (2014). Ebola Clinical Care Guidelines. Available from: Clinical%20Care%20Guide lines%202%20sep% pdf (accessed 26 February 2015). 14. Centres for Disease Control and Prevention (2015). Recommendations for Safely Performing Acute Hemodialysis in Patients with Ebola Virus Disease (EVD) in U.S. Hospitals. Available at: (accessed 13 February 2015). 15. Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. NEJM 2014; 371: American Academy of Pediatrics (2014). Ebola FAQs. Available: (accessed 11 February 2015) Volume 31 final.indd 54 16/05/ :16
Media centre Ebola virus disease
1 of 6 10/15/2014 10:59 AM Media centre Ebola virus disease Fact sheet N 103 Updated September 2014 Key facts Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a severe, often fatal
More informationSummary of current outbreak in Guinea, Liberia and Sierra Leone
ALERT TO HEALTHCARE WORKERS: EBOLA VIRUS DISEASE OUTBREAK IN GUINEA, LIBERIA AND SIERRA LEONE, WEST AFRICA 04 April 2014 Summary of current outbreak in Guinea, Liberia and Sierra Leone In this update and
More information12 June The average EVD case fatality rate has been around 50 per cent.
12 June 2015 Ebola virus was first identified in Sudan and Zaire in 1976. It belongs to the family of Filoviridae. It causes Ebola Virus Disease (EVD), formerly known as Ebola Hemorrhagic Fever. EVD is
More informationUTSW/BioTel EMS TRAINING BULLETIN October EMS TB Ebola Virus Disease (EVD)
UTSW/BioTel EMS TRAINING BULLETIN October 2014 EMS TB 14-006 Ebola Virus Disease (EVD) Purpose: 1. To inform & provide management recommendations to UTSW/BioTel EMS System EMS Providers about Ebola Virus
More informationEbola Virus Patient Advisory
22 September 2014 Ebola Virus Patient Advisory Introduction Ebola virus was first identified in Sudan and Zaire in 1976. It belongs to the family of Filoviridae. It causes Ebola Virus Disease (EVD), formerly
More informationInformation for Primary Care: Managing patients who require assessment for Ebola virus disease Updated 17 Oct 2014
Information for Primary Care: Managing patients who require assessment for Ebola virus This guidance is aimed at clinical staff undertaking direct patient care in primary care, including GP surgeries,
More informationEDUCATIONAL COMMENTARY EMERGING INFECTIOUS DISEASES WITH GLOBAL IMPACT
Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn CE Credits under Continuing Education on
More informationEbola. Wessex CPD Event 14/11/14. Dr Ishani Kar-Purkayastha, CCDC, Wessex PHE Centre Tel:
Ebola Wessex CPD Event 14/11/14 Dr Ishani Kar-Purkayastha, CCDC, Wessex PHE Centre wessex@phe.gov.uk Tel: 0345 055 2022 Outline Background About the current outbreak Situation in the UK Clinical management
More informationEbola Virus Disease (EVD) Essential information
Ebola Virus Disease (EVD) Essential information Ebola Virus Disease (EVD) Origins The Ebola virus is named after the Ebola River in what was Zaire (now Democratic Republic of Congo) where the first outbreak
More informationKey Points Ebola Virus Disease, West Africa Newly updated information is indicated in red
Key Points Ebola Virus Disease, West Africa Newly updated information is indicated in red In this document: Summary Key Messages Ebola Cases and Deaths (West Africa) Ebola in U.S. Health Workers (in Liberia)
More informationGenus Ebolavirus is 1 of 3 members of the Filoviridae family (filovirus), along with genus Marburgvirus and genus Cuevavirus.
EBOLA VIRUS Ebola virus disease (EVD) is a severe, often fatal illness, with a case fatality rate of up to 90%. It is one of the world s most virulent diseases.the infection is transmitted by direct contact
More informationEBOLA 101. Update for EMS System Stakeholders. Eric M. Rudnick, MD, FACEP, FAAEM Medical Director Nor Cal EMS Version 10/25/2014
EBOLA 101 Update for EMS System Stakeholders Eric M. Rudnick, MD, FACEP, FAAEM Medical Director Nor Cal EMS Version 10/25/2014 Conference 1 Version #1 Date 10/25/14 Content good for current situation 10/25/14
More informationThe Ebola Virus. By Emilio Saavedra
The Ebola Virus By Emilio Saavedra Etiological Agents: Ebolavirus is the etiologic agent. [1] There are four main families of viruses that are agents of Ebola (hemorrhagic fever). [1] These four families
More informationCDC Ebola Response Team
Ebola Preparations from the Healthcare Epidemiologists Perspective August 25th, 2014 CDC Ebola Response Team Barbara Knust, DVM, MPH Epidemiology Team Lead Tim Uyeki, MD Clinical Team Lead Nancy Cornish,
More informationQuestions and Answers on Ebola
Updated: August 26, 2014 The 2014 Ebola outbreak is the largest Ebola outbreak in history and the first in West Africa. The current outbreak is affecting four countries in West Africa: Guinea, Liberia,
More informationEBOLA FACTS. During this outbreak, most of the disease has spread through human-to-human transmission.
EBOLA FACTS Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe and often fatal illness, with a fatality rate of up to 90%. It is one of the world s most dreaded diseases. However,
More informationPalliative Care in Ebola
Palliative Care in Ebola CHALLENGES IN DELIVERY AND EXPERIENCES FROM THE CURRENT OUTBREAK Background Ebola: filovirus from the family filoviridae Named after the Ebola River in DRC (then Zaire) where first
More informationEBOLA VIRUS Guidance for Michigan local health departments and healthcare providers
EBOLA VIRUS Guidance for Michigan local health departments and healthcare providers VERSION 2 Interim Guidelines for Evaluation of US Patients Suspected of Having Ebola Virus Disease (EVD) This is a rapidly
More informationEbola Virus Transmission
Ebola Virus Zoonotic virus bats the most likely reservoir, although species unknown Spillover event from infected wild animals (e.g., fruit bats, monkey, duiker) to humans, followed by human-human transmission
More informationDistribution: As Appendix 1 Dr Ruth Hussey, Chief Medical Officer, Welsh Government Date: 10 October Ongoing Ebola outbreak in West Africa
Public Health Link From the Chief Medical Officer for Wales Distribution: As Appendix 1 From: Dr Ruth Hussey, Chief Medical Officer, Welsh Government Date: 10 October 2014 Reference: Category: Title: What
More informationMarburg virus disease
Marburg virus disease Fact sheet available at http://www.who.int/mediacentre/factsheets/fs_marburg/en/ Updated 20 October 2017 Key facts Marburg virus disease (MVD), formerly known as Marburg haemorrhagic
More informationPROFESSOR DAME SALLY C DAVIES CHIEF MEDICAL OFFICER CHIEF SCIENTIFIC ADVISER
Richmond House 79 Whitehall London SW1A 2NS Tel: +44 (0)20 7210 4850 http://www.info.doh.gov.uk/contactus.nsf/memo?openform 7 October 2014 For Action General Practitioners, England Accident and Emergency
More informationEbola Outbreak deadly infectious diseases as a potential major threat. Dilys Morgan
Ebola Outbreak deadly infectious diseases as a potential major threat Dilys Morgan Ebola Virus Disease (EVD) 1976: First documented outbreak in Zaïre (now: the Democratic Republic of Congo) The incubation
More informationProvider Health & Safety Alert Ebola Virus Disease September 30, 2014
Provider Health & Safety Alert Ebola Virus Disease September 30, 2014 With the announcement of the first confirmed case of Ebola Virus Disease (EVD) in Dallas Texas, there could be interactions with individuals
More informationStatements about Ebola: True or false? Part 1 Commented version for trainers only!
Statements about Ebola: True or false? Part 1 Commented version for trainers only! The questions and answers are designed to revise key messages of the training. If necessary, you may adapt the questions
More informationEbola Virus Disease: Occupational Safety and Health
Ebola Virus Disease: Occupational Safety and Health Joint WHO/ILO Briefing Note for Workers and Employers 25 August 2014 (update 5 September 2014) This briefing note is based on the existing WHO and ILO
More informationTRAVEL ADVISORY TO PREVENT THE IMPORTATION OF EBOLA INTO SOUTH AFRICA
TRAVEL ADVISORY TO PREVENT THE IMPORTATION OF EBOLA INTO SOUTH AFRICA The purpose of this advisory is to notify travellers about the Ebola disease outbreak and inform them about preventative measures they
More informationEbola Virus Disease. What the physician needs to know. (Overview, Transmission and Clinical Features)
Ebola Virus Disease What the physician needs to know (Overview, Transmission and Clinical Features) Sources: Centers for Disease Control and Prevention (CDC) guidelines (www.cdc.gov) and WHO guidelines
More informationEbola Virus Diseases
CDC/Dr F A Murphy Frequently Asked Questions on Ebola Virus Diseases Frequently asked questions on Ebola virus disease World Health Organization 2014 All rights reserved. Requests for publications, or
More informationInfection Control Precautions during the Clinical Management of Injecting Drug Users with Possible, Probable or Confirmed Anthrax
Infection Control Precautions during the Clinical Management of Injecting Drug Users with Possible, Probable or Confirmed Anthrax (Adapted from guidance developed by Health Protection Scotland and HPA
More informationsaipem Ebola virus diseases EVD August 2014
Ebola virus diseases EVD August 2014 Why Ebola generates such fear? Ebola is one of the world's most deadly diseases. It can kill up to 90% of people who developed Ebola virus disease. There is not treatment
More informationEbola Virus Disease. Global Epidemiology and Surveillance in Hong Kong. as of 13 August 2014
Ebola Virus Disease Global Epidemiology and Surveillance in Hong Kong as of 13 August 2014 Ebola Virus Disease (EVD) Ebola virus disease (EVD), (formerly known as Ebola haemorrhagic fever) is a severe,
More information4. Laboratory Diagnosis of Viral Haemorrhagic Fever Viruses
4. Laboratory Diagnosis of Viral Haemorrhagic Fever Viruses 4.1 Introduction Early infection with VHF is characterised by a short non-specific viral prodrome with an extensive differential diagnosis. The
More informationGrace Kubin, Ph.D. 10 th Annual Alabama Laboratory Meeting 2015
Grace Kubin, Ph.D. 10 th Annual Alabama Laboratory Meeting 2015 Viral hemorrhagic fever Member of Filoviridae family Ebolavirus genera: Zaire 50-90% fatality rate Sudan 50% fatality rate Bundibugyo 30%
More informationThis SOP applies to all staff employed by NHS Greater Glasgow & Clyde and locum staff on fixed term contracts and volunteer staff.
Page 1 of 8 SOP Objective To ensure that Healthcare Workers (HCWs) are aware of the actions and precautions necessary to minimise the risk of outbreaks and the importance of diagnosing patients clinical
More informationEbola Virus Disease: the Facts, Response & the Way Forward. Dr. Abraham Idokoko Ebola Emergency Operations Centre (EEOC), Lagos.
Ebola Virus Disease: the Facts, Response & the Way Forward. Dr. Abraham Idokoko Ebola Emergency Operations Centre (EEOC), Lagos. 2 Yearly trend of Emergence of New Infectious Diseases Globally, an average
More informationConfronting Ebola. Keeping NY patients and healthcare workers safe and healthy
Confronting Ebola Keeping NY patients and healthcare workers safe and healthy All materials provided by Centers for Disease Control and Prevention. October 16, 2014 What You Need to Know about Ebola The
More informationFigure 1: Ebola Virus strengthens the framework for a scaled-up response.
A n insight into ebola virus The outbreak of Ebola virus disease in West Africa continues to escalate, with 2615 cases and 1427 deaths reported from Guinea, Liberia, Nigeria, and Sierra Leone. Extensive
More informationThis SOP applies to all staff employed by NHS Greater Glasgow & Clyde and locum staff on fixed term contracts and volunteer staff.
Page 1 of 9 Review SOP Objective To ensure that Healthcare Workers (HCWs) are aware of the actions and precautions necessary to minimise the risk of outbreaks and the importance of diagnosing patients
More informationModes of Transmission of Influenza A H1N1v and Transmission Based Precautions (TBPs)
Modes of Transmission of Influenza A H1N1v and Transmission Based Precautions (TBPs) 8 January 2010 Version: 2.0 The information contained within this document is for the use of clinical and public health
More informationTRAVEL ADVISORY TO PREVENT THE IMPORTATION OF EBOLA INTO SOUTH AFRICA
TRAVEL ADVISORY TO PREVENT THE IMPORTATION OF EBOLA INTO SOUTH AFRICA The purpose of this advisory is to notify travellers about the Ebola disease outbreak and inform them about preventative measures they
More informationHealth care workers (HCWs) caring for suspected (clinically diagnosed) or confirmed cases of. Influenza A(H1N1)v FREQUENTLY ASKED QUESTIONS
Health care workers (HCWs) caring for suspected (clinically diagnosed) or confirmed cases of Questions found here: FREQUENTLY ASKED QUESTIONS What is pandemic flu? What is the difference between seasonal
More informationEbola virus disease. Nicholas J Beeching, 1 2 Manuel Fenech, 2 Catherine F Houlihan 3 EDUCATION CLINICAL REVIEW
Link to this article online for CPD/CME credits Ebola virus disease Nicholas J Beeching, 1 2 Manuel Fenech, 2 Catherine F Houlihan 3 1 Liverpool School of Tropical Medicine, Royal Liverpool University
More informationThe presenter has no potential or actual conflicts of interest and no relevant financial relationships to maters regarding or related to Ebola.
Leonard A. Levy, DPM, MPH Associate Dean of Research and Innovation Director, Institute for Disaster and Emergency Preparedness Professor of Public Health/Family Medicine/Biomedical Informatics Nova Southeastern
More informationEBOLA. Harford County Health Department October 22, 2014
EBOLA Harford County Health Department October 22, 2014 Zaire ebolvirus The 2014 Ebola outbreak concerns the most deadly of the five Ebola viruses, Zaire ebolvirus, which has killed 79 percent of the people
More informationSeasonal Influenza in Pregnancy and Puerperium Guideline (GL1086)
Seasonal Influenza in Pregnancy and Puerperium Guideline (GL1086) Approval Approval Group Job Title, Chair of Committee Date Maternity & Children s Services Clinical Governance Committee Chair, Maternity
More informationInfectious Disease Outbreaks in confined spaces
Infectious Disease Outbreaks in confined spaces Dr Andrew Ebringer Senior Medical Director, Medical Services - Australia International SOS 1 2013 AEA International Holdings Pte. Ltd. All rights reserved.
More informationUNICEF s Response to the Ebola Crisis. Presenta(on to the Execu(ve Board, Informal Session, 11 September 2014
UNICEF s Response to the Ebola Crisis Presenta(on to the Execu(ve Board, Informal Session, 11 September 2014 Overview Over 2,200+ deaths and over 4,200 confirmed / probable cases in Guinea, Sierra Leone,
More informationWHO SOUTHERN SUDAN HEALTH UPDATE May 2004
WHO SOUTHERN SUDAN HEALTH UPDATE SPECIAL EDITION: EBOLA Ebola outbreak confirmed in Yambio, Western Equatoria World Health Organization leads international response team to contain the outbreak Photo by:
More informationViral Hemorrhagic Fevers
Viral Hemorrhagic Fevers (VHFs) http://www.ncrr.nih.gov/publications/ncrr_reporter/summer-fall2009/images/essential_2.jpg Definition Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are
More informationU.S. CDC s Response to the Ebola Outbreak
U.S. CDC s Response to the Ebola Outbreak CAPSCA Global Meeting Cairo, Egypt November 17-19, 2014 Susan Lippold, MD, MPH Ebola Response, Global Migration Task Force Division of Global Migration and Quarantine
More informationCDC Health Advisory 04/29/2009
H1N1 (Swine Flu) is a sub-type of Influenza A. Wexford Labs disinfectants are effective against Influenza A. Current CDC Recommendations for Environmental Control in the Healthcare Setting: CDC Health
More informationEBOLA VIRUS AWARENESS
EBOLA VIRUS AWARENESS Yvonne S. Butler, MD Assistant Professor; Obstetrics and Gynecology Global Women s Health Program Liberia Chevron-Liberia / BIPAI Partnership Baylor College of Medicine Texas Children
More informationEBOLA INFORMATION KIT 20 to 26 October 2014 MEMBERS NEWS HUNTING SERVICES FUND LEGISLATION CALENDAR GENERAL SHOP POPULAR ARTICLES
HOME ABOUT PHASA MEMBERS NEWS HUNTING SERVICES FUND LEGISLATION CALENDAR GENERAL SHOP DOWNLOAD: PROFESSIONAL HUNTER STATUS SECTION 16A (click to download) DOWNLOADS NEWSLETTERS F.A.Q TWITTER FACEBOOK Home
More informationBureau of Emergency Medical Services New York State Department of Health
Swine Influenza A (H1N1) Advisory To: All EMS Agencies From: Disaster Preparedness Unit Date: April 28, 2009 Introduction The Bureau of Emergency Medical Services is providing the following update regarding
More informationAppendix C. RECOMMENDATIONS FOR INFECTION CONTROL IN THE HEALTHCARE SETTING
Appendix C. RECOMMENDATIONS FOR INFECTION CONTROL IN THE HEALTHCARE SETTING Infection Control Principles for Preventing the Spread of Influenza The following infection control principles apply in any setting
More informationMaking Sense Of The Ebola Virus
Fodder for young minds Making Sense Of The Ebola Virus By Meera Dolasia on September 29, 2014 CCSS NAS-6 Grades: 5-8 Word Search Every few years, a new pandemic hits the globe and sends shivers down everyone's
More informationInfluenza Outbreak Control Measure Trigger Tool for Care Homes
Influenza Outbreak Control Measure Trigger Tool for Care Homes To be used on instruction of your Health Protection Teams (HPT) The control measures in this tool are in addition to Standard Infection Control
More informationSURVEILLANCE SURVEILLANCE-- OR LACK OF OR LACK OF
Issues in Infection Control Geeta Mehta MD,MPH President HISI www.hisindia.org Current Issues in Infection Control SURVEILLANCE- OR LACK OF IT! CDC (1998) Definition of Surveillance the ongoing systematic
More informationSlide 1. Slide 2. Slide 3 EBOLA 2014 WEST AFRICA CENTRAL AND EAST AFRICA. Hosted by: Bhagavatula Ramakrishna, M.D.
Slide 1 EBOLA 2014 WEST AFRICA Hosted by: Bhagavatula Ramakrishna, M.D. Slide 2 CENTRAL AND EAST AFRICA Slide 3 Slide 4 EBOLA IN WEST AFRICA 2014 Slide 5 It is a disease of poverty and neglect of health
More informationDoc: 1.9. Course: Patient Safety Solutions. Topic: Infection prevention and control. Summary
Course: Patient Safety Solutions Topic: Infection prevention and control Summary Health care-associated Infection (HCAI) is defined as an infection acquired in a hospital by a patient who was admitted
More informationCIRCULAR LETTER No
CIRCULAR LETTER No 06-204 0.0.203 To: MASTER CREW MEMBERS 07 th August, 204 URGENT Due to the serious nature of the outbreak of the Ebola virus in West Africa, the following 5 safe precautions to be strictly
More informationPandemic Influenza Infection Control Measures
NHS Greater Glasgow & Clyde Partnerships Pandemic Influenza Infection Control Measures Guidance for Community Staff April 2009 Introduction This presentation aims to provide you with the key information
More informationChapter 11 PREVENTING INFECTION. Elsevier items and derived items 2010 by Mosby, Inc. an affiliate of Elsevier Inc. All rights reserved
Chapter 11 PREVENTING INFECTION Infection is a major safety and health hazard. The health team follows certain practices and procedures to protect patients, residents, visitors, and staff from infection.
More informationOUR COMMUNITY: OUR WORLD: ONE HEALTH. Ebola : Geomedicine Conference
OUR COMMUNITY: OUR WORLD: ONE HEALTH Ebola 2013-14: Geomedicine Conference Early Geomedicine East Africa, El Nino 1997 RVF: A One Health Response Ecological prediction models Animal vaccination Human
More informationPUBLIC HEALTH SIGNIFICANCE SEASONAL INFLUENZA AVIAN INFLUENZA SWINE INFLUENZA
INFLUENZA DEFINITION Influenza is an acute highly infectious viral disease characterized by fever, general and respiratory tract catarrhal manifestations. Influenza has 3 Types Seasonal Influenza Avian
More informationبسم اهلل الرحمن الرحيم
بسم اهلل الرحمن الرحيم INFECTION CONTROL MEASURES AGAINST H1N1 VIRUS; PHASE II Microbiology Diagnostics and Infection Control UNIT () Mansoura University Hospitals Prof. Mohammad Abou el-ela Director of
More informationSCOTTISH AMBULANCE SERVICE Strategic Co-ordination Centre (SCC) Bulletin 01/ April Swine Flu-Information Sheet
SCOTTISH AMBULANCE SERVICE Strategic Co-ordination Centre (SCC) Bulletin 01/09 Swine Flu-Information Sheet To date 2 cases of swine Influenza A (H1N1) have been confirmed in individuals in Scotland. Other
More informationViral Hemorrhagic Fevers CDC, AFIP
CDC, AFIP Diverse group of illnesses caused by RNA viruses from 4 families: Arenaviridae, Bunyaviridae, Filoviridae, Flaviridae Differ by geographic occurrence and vector/reservoir Share certain clinical
More informationINTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION a Society that includes Basic Science, the Failing Heart, and Advanced Lung Disease
International Society of Heart and Lung Transplantation Advisory Statement on the Implications of Pandemic Influenza for Thoracic Organ Transplantation This advisory statement has been produced by the
More informationEbola Exposure (Version )
Ebola Exposure (Version 10-28-14) Pediatric Office-Hours Version DEFINITION Exposure to a person with suspected or proven Ebola Travel to or living in an area with recent cases of Ebola. These are countries
More informationPersonal Protective Equipment, Hand Hygiene and Surface Cleaning in the context of Ebola
Personal Protective Equipment, Hand Hygiene and Surface Cleaning in the context of Ebola This publication and the information it contains is intended for distribution to, or use by, people in the following
More informationManagement of Outbreaks Care Homes IPC Study Day
Management of Outbreaks Care Homes IPC Study Day Sue Barber Infection Prevention & Control Lead AV & Chiltern CCG s Diarrhoea and/or vomiting May be bacterial or viral May be non-infectious in origin but
More informationEBOLA & OTHER VIRUSES IN THE NEWS EBOLA VIRUS, CHIKUNGUNYA VIRUS, & ENTEROVIRUS D68
EBOLA & OTHER VIRUSES IN THE NEWS EBOLA VIRUS, CHIKUNGUNYA VIRUS, & ENTEROVIRUS D68 PRESENTERS Patricia Quinlisk, MD, MPH, Medical Director /State Epidemiologist Samir Koirala, MBBS, MSc Epidemic Intelligence
More informationCase study: Epidemic modelling in real life
Case study: Epidemic modelling in real life Epidemic modelling, simulation and statistical analysis Stockholm 2015. Sharon Kühlmann-Berenzon 2015-11-09 Outline for the day 1.Epidemic modelling: what is
More informationVIRAL HEMORRHAGIC FEVER (VHF)
VIRAL HEMORRHAGIC FEVER (VHF) REPORTING INFORMATION Class A: Report immediately via telephone the case or suspected case and/or a positive laboratory result to the local public health department where
More informationTravel and transport risk assessment. Preparedness for potential outbreak of
Travel and transport risk assessment Preparedness for potential outbreak of Ebola Interim virus guidance disease: for A public framework health for authorities and action the transport in the Western sector
More informationEpidemic Ebola Virus Disease Understanding, demystifying and controlling a frightening disease Republic of Guinea, 2014
Epidemic Ebola Virus Disease Understanding, demystifying and controlling a frightening disease Republic of Guinea, 2014 James A. Zingeser, DVM, MPH Food and Agriculture Organization of the UN Rome, Italy
More informationChapter 12. Preventing Infection. Elsevier items and derived items 2014, 2010 by Mosby, an imprint of Elsevier Inc. All rights reserved.
Chapter 12 Preventing Infection Infection Infection is a major safety and health hazard. The health team follows certain practices and procedures to protect patients, residents, visitors, and staff from
More informationHepatitis B is a virus that attacks the liver. It is highly infectious. Hepatitis B is transmitted primarily
BLOOD BORNE PATHOGENS TRAINING FOR SCHOOL STAFF Blood Borne Pathogen (BBP): A blood borne pathogen is defined as an organism found in human blood or other infected body fluids that may cause disease in
More informationDr. Johnmark Opondo MB. ChB. (Nairobi UON), MPH ( Emory) Deputy Medical Health Officer Saskatoon Health Region
Dr. Johnmark Opondo MB. ChB. (Nairobi UON), MPH ( Emory) Deputy Medical Health Officer Saskatoon Health Region OBJECTIVES 1. To understand the basic science behind EVD 2. To review the issues behind the
More informationEbola: 22,000 cases, 8700 deaths. Enterovirus D68: 1100 cases, 14 deaths. Chikungunya virus: almost a million cases in the Western Hemisphere
Sally Williams MD Ebola: 22,000 cases, 8700 deaths Enterovirus D68: 1100 cases, 14 deaths Chikungunya virus: almost a million cases in the Western Hemisphere } A nonpolio enterovirus identified in 1962,
More informationU.S. and British troops head to West Africa to help fight Ebola virus
U.S. and British troops head to West Africa to help fight Ebola virus By Los Angeles Times, adapted by Newsela staff - Sept. 09, 2014 1 2 3 4 To slow down the spread of the deadly virus Ebola, the United
More informationFolks: The attached information is just in from DOH. The highlights:
Folks: The attached information is just in from DOH. The highlights: ALL ILI (influenza-like illness) should be considered to be flu. It doesn't matter if it's H1N1, or some other strain. It all spreads
More informationCHAPTER 7 Medical/Surgical Asepsis and Infection Control
CHAPTER 7 Medical/Surgical Asepsis and Infection Control 1 Slide 1 Microorganisms Microscopic. Naturally present on and in the human body and environment. Some microorganisms (pathogens) cause specific
More informationSevere Acute Respiratory Syndrome ( SARS )
Severe Acute Respiratory Syndrome ( SARS ) Dr. Mohammad Rahim Kadivar Pediatrics Infections Specialist Shiraz University of Medical Sciences Slides Designer: Dr. Ramin Shafieian R. Dadrast What is SARS?
More informationInfluenza-Associated Pediatric Mortality rev Jan 2018
rev Jan 2018 Infectious Agent Influenza A, B or C virus BASIC EPIDEMIOLOGY Transmission Transmission occurs via droplet spread. After a person infected with influenza coughs, sneezes, or talks, influenza
More informationPOLICY MEDICAL POLICY RE: INFECTION CONTROL. This policy applies to all School departments, including EYFS
POLICY MEDICAL POLICY RE: INFECTION CONTROL This policy applies to all School departments, including EYFS The transmission of the common cold, Influenza and more volatile viruses such as the Rotovirus
More informationPRESS STATEMENT ON MARBURG VIRUS DISEASE
THE REPUBLIC OF UGANDA MINISTRY OF HEALTH PRESS STATEMENT ON MARBURG VIRUS DISEASE Hon. Dr. Jane Ruth Aceng Minister of Health October 19, 2017 PRESS STATEMENT ON MARBURG HEMORRHAGIC FEVER The Ministry
More informationSOP Objective To provide Healthcare Workers (HCWs) with details of the precautions necessary to minimise the risk of RSV cross-infection.
Page 1 of 11 SOP Objective To provide Healthcare Workers (HCWs) with details of the precautions necessary to minimise the risk of RSV cross-infection. This SOP applies to all staff employed by NHS Greater
More informationChapter 13. Preventing Infection. Copyright 2019 by Elsevier, Inc. All rights reserved.
Chapter 13 Preventing Infection Copyright 2019 by Elsevier, Inc. All rights reserved. Lesson 13.1 Define the key terms and key abbreviations in this chapter. Identify what microbes need to live and grow.
More informationBloodborne Pathogens and Exposure Control
Bloodborne Pathogens and Exposure Control 2016 Information in the Exposure Control Plan The Bloodborne Pathogen Exposure Control Plan was developed to communicate information to you about: - Your risk
More informationNews in Review December 2014 Teacher Resource Guide EBOLA: A Deadly Virus Outbreak
News in Review December 2014 Teacher Resource Guide EBOLA: A Deadly Virus Outbreak Note to Teachers The classroom must promote a safe place for students to discuss sensitive issues such as illness and
More informationPANDEMIC INFLUENZA PHASE 6 INFECTION CONTROL RECOMMENDATIONS TEMPLATE
PANDEMIC INFLUENZA PHASE 6 INFECTION CONTROL RECOMMENDATIONS TEMPLATE (Updated September 7, 2006) Information and concept courtesy Of the San Francisco Public Health Department Table of Contents Pandemic
More informationUniversal Precautions
Universal Precautions emphasizes the need for workers and students to consider all blood and body fluids as potentially infected with HIV, HBV, and / or other blood-borne pathogens, and to adhere rigorously
More informationSwine Flu. Background. Interim Recommendations. Infectious Period. Case Definitions for Infection with Swine-origin
Page 1 of 5 Swine Flu Interim Guidance for Emergency Medical Services (EMS) Systems and 9-1-1 Public Safety Answering Points (PSAPs) for Management of Patients with Confirmed or Suspected Swine- Origin
More informationANNEX I: INFECTION CONTROL GUIDELINES FOR PANDEMIC INFLUENZA MANAGEMENT
ANNEX I: INFECTION CONTROL GUIDELINES FOR PANDEMIC INFLUENZA MANAGEMENT During an influenza pandemic, adherence to infection control practices is extremely important to prevent transmission of influenza.
More informationEbola Epidemic in Coastal West Africa Overall Situation
Ebola Epidemic in Coastal West Africa Overall Situation Report given at Caritas Internationalis Briefing Meeting 05 November 2014 Dr and Deacon Timothy Flanigan MD Professor of Medicine and Infectious
More informationLEARNING MODULE: INFECTION CONTROL BLOODBORNE PATHOGENS ISOLATION PRECAUTIONS PHARMACEUTICAL WASTE
LEARNING MODULE: INFECTION CONTROL BLOODBORNE PATHOGENS ISOLATION PRECAUTIONS PHARMACEUTICAL WASTE For Residents & Instructors ggbha.org Updated 6/18/2018 This learning module must be reviewed by residents
More informationA BSL-1 lab houses activities that require only standard microbial practices. These include:
BSL-1 A BSL-1 lab houses activities that require only standard microbial practices. These include: Work should be performed on an open lab bench or table Spills must be decontaminated immediately Infectious
More information